Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Zoetis Inc.
ZTSHealthcareGenerated Jul 5, 2026, 08:13 PM UTC
ZTS (Zoetis Inc.) analytical snapshot. Revenue grew +5.7% YoY to $8.54B. Net margin at 27.43% (expanding ▲). Return on equity 49.14%, ROA 16.46%, ROIC 0.00%. Market cap $31.36B at $74.80 per share. Trailing P/E 14.75, P/S 3.67, P/B 9.70. Graham number $29.66 (trades above intrinsic). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score 3 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFundamentals
Revenue grew +5.7% YoY to $8.54B. Net margin at 27.43% (expanding ▲). Return on equity 49.14%, ROA 16.46%, ROIC 0.00%.
- Revenue grew +5.7% YoY to $8.54B.
- Net margin at 27.43% (expanding ▲).
- Return on equity 49.14%, ROA 16.46%, ROIC 0.00%.
- Gross margin 0.00%, operating margin 0.00%.
- Free cash flow margin 18.97% ($1.62B).
- Net income up ▲ +10.9% YoY.
- Debt/equity 2.80, current ratio 3.15, net debt $7.10B.
- Asset turnover 0.56 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | $446.0M | 54.59 |
| 2017 | — | — | — | — | — | $440.0M | 22.80 |
| 2018 | $4.89B | — | 0.00 | 0.00 | 16.80 | $497.0M | 46.38 |
| 2019 | $5.31B | +8.6% | 0.00 | 0.00 | 16.28 | $1.12B | — |
| 2020 | $5.83B | +9.8% | 0.00 | 0.00 | 24.52 | $1.45B | 52.73 |
| 2021 | $6.26B | +7.5% | 0.00 | 0.00 | 23.96 | $1.33B | 39.80 |
| 2022 | $6.67B | +6.6% | 0.00 | 0.00 | 24.54 | $1.67B | 36.06 |
| 2023 | $7.78B | +16.5% | 0.00 | 0.00 | 26.20 | $1.74B | 46.24 |
| 2024 | $8.08B | +3.9% | 0.00 | 0.00 | 26.16 | $1.33B | 42.31 |
| 2025 | $8.54B | +5.7% | 0.00 | 0.00 | 27.43 | $1.62B | 49.14 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $2.20B | +0.4% | — | 28.71% |
| Jun 30, 2025 | $4.68B | +2.8% | +112.9% | 28.82% |
| Jun 30, 2025 | $2.46B | -45.9% | -47.4% | 54.84% |
| Sep 30, 2025 | $7.08B | +2.0% | +187.8% | 29.24% |
| Sep 30, 2025 | $2.40B | -65.4% | -66.1% | 86.25% |
| Mar 31, 2026 | $2.26B | +1.9% | -5.8% | 26.57% |
Filings & Ownership
Latest annual report (10-K) filed Feb 12, 2026. Latest quarterly report (10-Q) filed May 7, 2026. 10 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 12, 2026.
- Latest quarterly report (10-Q) filed May 7, 2026.
- 10 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
| Date | Form | Description |
|---|---|---|
| May 22, 2026 | 8-K | 8-K |
| May 20, 2026 | 8-K | 8-K |
| May 7, 2026 | 8-K | 8-K |
| Feb 12, 2026 | 8-K | 8-K |
| Feb 5, 2026 | 8-K | 8-K |
| Dec 18, 2025 | 8-K | 8-K |
| Dec 11, 2025 | 8-K | 8-K |
| Dec 2, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
No significant implicit signals detected. Key metrics are changing within normal ranges.
- Endogenous analysis: No significant implicit signals detected in the latest filing. Key metrics are changing within normal ranges — the filing appears consistent with prior-period patterns.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $8.08B | $8.54B | $464.0M | +5.7% |
| Net income | $2.11B | $2.34B | $230.0M | +10.9% |
| Operating cash flow | $1.91B | $2.35B | $441.0M | +23.1% |
| Capex | $586.0M | $732.0M | $146.0M | +24.9% |
| Total assets | $14.29B | $14.24B | $-49.0M | -0.3% |
| Total liabilities | $9.29B | $9.47B | $172.0M | +1.9% |
| Long-term debt | $6.56B | $5.22B | $-1.34B | -20.5% |
| Cash & equivalents | $610.0M | $882.0M | $272.0M | +44.6% |
| Stockholders equity | $5.00B | $4.77B | $-227.0M | -4.5% |
| Inventory | $2.56B | $2.31B | $-258.0M | -10.1% |
| Accounts receivable | $1.30B | $1.32B | $12.0M | +0.9% |
| SG&A expense | $2.01B | $2.15B | $142.0M | +7.1% |
| Interest expense | $221.0M | $239.0M | $18.0M | +8.1% |
| Type | Concepts |
|---|---|
| Removed | AccruedLiabilitiesCurrent, AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium, AdvertisingExpense, AllocatedShareBasedCompensationExpenseNetOfTax, AssetRetirementObligationsNoncurrent, BuildingsAndImprovementsGross, BusinessExitCosts1, CapitalizedComputerSoftwareAmortization1, CapitalizedComputerSoftwareNet, CommonStockDividendsPerShareCashPaid |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Related party transactions | low | 17 | 0 | NEW |
Unlock the rest
- ProValuationMarket cap $31.36B at $74.80 per share.
- ProPrice & TechnicalsPrice $74.80 — downtrend (below 200-DMA); 1-month momentum negative.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite 3
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Zoetis Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+5.7%** YoY to $8.54B..
Peer comparison
Defensive groupHow ZTS stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS● you | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |